期刊文献+

利用Caco-2细胞模拟羟基喜树碱在小肠内吸收的研究 被引量:1

Absorption of hydroxycamptothecin by simulating epithelial cells of intestine with Caco-2 cells
下载PDF
导出
摘要 目的研究羟基喜树碱在小肠内的可能吸收机制。方法采用Caco-2细胞模型模拟小肠上皮细胞,研究质量浓度、表面活性剂和P-gp抑制剂对羟基喜树碱的跨膜吸收与转运的影响,总结羟基喜树碱的吸收与转运规律,通过数据分析推断出羟基喜树碱在小肠内的可能吸收机制。结果药物摄取量随质量浓度的增加而非线性增加。表面活性剂和P-gp抑制剂的加入都能增加药物的跨膜吸收量与转运速率。结论羟基喜树碱的跨膜吸收可能受到P-gp的外排作用。 AIM To study the absorption mechanism of hydroxycamptothecin(HCPT) in small intestines.METHODS Caco-2 cell model was used to simulate small intestinal epithelial cells.The influence of concentration,surfactant and P-gp inhibitors on the absorption across membrane of HCPT was studied.The absorption mechanism of HCPT from the small intestines was concluded by analyzing the data.RESULTS In the cell test of the different HCPT concentrations,the results showed the intake of HCPT increased nonlinearly with the increase of HCPT concentration.The results in the influencing test proved that surfactant and P-gp inhibitors could increase the absorptivity and transport rate of HCPT across cell monolayer.CONCLUSION The experimental results show that the absorption process of HCPT is possibly affected by P-gp.
出处 《中成药》 CAS CSCD 北大核心 2012年第7期1203-1208,共6页 Chinese Traditional Patent Medicine
基金 国家重点基础研究发展计划(973项目)(2009CB930300) 国家自然基金项目(81173008)
关键词 羟基喜树碱 纳米混悬剂 CACO-2细胞 摄取与转运 hydroxycamptothecin nanosuspension Caco-2 cell intake and transport
  • 相关文献

参考文献11

  • 1Gupta E, Luo F, Law A, et al. camptothecin, a highly lipophilic mediated by active transporter ( s ) 20(2A) : 1013-1016. The intestinal absorption of drug, across Caco-2 cells is [J]. Anticancer Res, 2000,.
  • 2郑晓清,张钧寿.羟基喜树碱自微乳的制备及大鼠体内药动学[J].中国药科大学学报,2008,39(2):132-135. 被引量:9
  • 3Kotze A F, Luessen H L, De Leeuw B J, et al. N-trimethyl chi- tosan chloride as a potential absorption enhancer across mucosal surfaces : in vitro evaluation in intestinal epithelial cells ( Caco- 2)[J]. Pharm Res, 1997, 14(9): 1197-1202.
  • 4Jonke C, Hamman J H, Kotz6 A F. Intestinal paracellular per- meation enhancement with quaternised chitosan: in situ- and in vitro evaluation[ J]. lnt J Pharm, 2002, 238 (1/2) : 205-213.
  • 5洪庆涛,宋岳涛,唐一鹏,刘春梅.细胞培养液乳酸脱氢酶漏出率的比色测定及其应用[J].细胞生物学杂志,2004,26(1):89-92. 被引量:70
  • 6胡一桥,郑梁元,钱陈钦,郁伟海.离子型药物酚红的小肠吸收研究[J].中国药科大学学报,1996,27(6):355-359. 被引量:56
  • 7Behrens I, Kissel T. Do cell culture conditions influence the car- rier-mediated transport of peptides in Caco-2 cell monolayers [J]. Eur J Pharm Sci, 2003, 19(5):433442.
  • 8Creemers G J, Gervits C J H, Eckhardt J. Phase I and pharma- cologic study of oral topotecan administrered twice daily for 21 days to adult patients with solid tumors[ J]. J Clin Oncol, 1997, 15(3) : 1087-1093.
  • 9Kruijtzer C M F, Beijnen J H, Rosing H, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918 [ J]. J Clin Oncol, 2002, 20( 13): 2943-2950.
  • 10沙先谊,方晓玲,吴云娟.9-硝基喜树碱在Caco-2细胞模型中的体外摄取、转运及外排动力学[J].药学学报,2004,39(10):839-843. 被引量:21

二级参考文献32

  • 1邵京山,薛敏,冯玉兰,曹黎波,于峻.复方丹参注射液对脑出血CT及脑脊液LDH的影响[J].实用中西医结合临床,2002,2(5):1-2. 被引量:1
  • 2[1]Pantazis P, Earuj JA, Kozielski AJ, et al. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro [J]. Cancer Res, 1993,53(7) :1577 - 1582.
  • 3[2]Sands H, Mishra A, Stoeckler JD, et al. Preclinical activity of an iv formulation of rubitecan in IDD-PTM against human solid tumor xenografts [ J ]. Anticancer Drugs, 2002,13 (9): 965 - 975.
  • 4[3]Zhong DF, Li K, Xu JH, et al. Pharmacokinetics of 9-nitro-20 (S) -camptothecin in rats [ J ]. Acta Pharmacol Sin, 2003,24 (3) :256 - 262.
  • 5[4]Creemers GJ, Gervits CJH, Eckhardt J. Phase Ⅰ and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors [J].J Clin Oncol, 1997,15(3) :1087 - 1090.
  • 6[5]Chu XY, Suzuki H, Ueda K, et al. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines[J]. J Pharmacol Exp Ther , 1999,288(2) :735 -741.
  • 7[6]Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport[J]. Adv DrugDeliv Rev, 2001,46(1 -3):27 -43.
  • 8[7]Hu M, Chen J, Zhu Y, et al. Mechanism and kinetics of transcellular transport of a new lactam antibiotic loracarbef across an human intestinal epithelial model system (Caco-2) [J]. PharmRes, 1994,11(12):1405-1413.
  • 9[8]Monkkonen H, Tormalehto S, Asunmaa K, et al.Cellular uptake and metabolism of clodronate and its derivatives in Caco-2 cells: a possible correlation with bisphosphonate-induced gastrointestinal side-effects [J].Eur J Pharm Sci, 2003,19( 1 ) :23 -29.
  • 10[9]Warner DL, Burke TG. Simple and versatile highperformance liquid chromatographic method for the simultaneous quantity of the lactone and carboxylate forms of camptothecin anticancer drugs [ J ]. J Chromatogr B Biomed Appl, 1997,691 ( 1 ): 161 - 171.

共引文献150

同被引文献10

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部